Aravive Inc (FRA:VE11)
€ 0.0325 0 (0%) Market Cap: 2.72 Mil Enterprise Value: -2.92 Mil PE Ratio: 0 PB Ratio: 1.74 GF Score: 0/100

Aravive Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 12:30PM GMT
Release Date Price: €1.56 (+6.12%)
Shreya Chowdhry
Jefferies - Analyst

Hello. Good morning, everyone. Welcome to the 2023 Jefferies Global Healthcare Conference Day 3. My name is Shreya Chowdhry; I'm from the Jefferies Healthcare Investment Banking team. It's my pleasure today to welcome the CEO of Aravive, Inc., Gail McIntyre. Thanks so much for being here today.

Gail McIntyre
Aravive, Inc. - CEO & Board Director

Thank you, and we really appreciate Jefferies inviting us to this great conference. So I'm going to have some forward-looking statements. So here's the typical precautions.

So Aravive has a pipeline built around one drug. It's called batiraxcept, and we are currently in late-stage Phase 3 platinum-resistant ovarian cancer program or study. And we expect data readout probably in August of this year. So we'll have topline data in August, and if those data are positive, we will be prepared to file a BLA by the end of this year.

We also are starting batiraxcept in clear cell renal cell carcinoma, and we actually have looked at both the second line as well as the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot